Navigation Links
MedImmune to Present 11 Abstracts on Influenza at 45th Annual National Immunization Conference
Date:3/29/2011

WASHINGTON, March 29, 2011 /PRNewswire/ -- MedImmune announced today it will present a total of 11 abstracts at the 45th National Immunization Conference (NIC) at the Washington Hilton in Washington, DC, March 28 - 31, 2011.  These abstracts advance the body of existing data and knowledge surrounding influenza prevention and trends in vaccination, highlighting MedImmune's strong leadership in patient health in various medical settings.

"MedImmune is pleased to announce new research on school-located influenza vaccination programs and use of influenza vaccines in special populations," said William Martone, MD, senior vice president of medical and scientific affairs at MedImmune. "We believe the data being presented at NIC will help the medical community explore innovative ways to prevent influenza in and outside of the medical home."

MedImmune abstracts to be presented at NIC on school-located influenza vaccination programs include:

  • Factors Associated with Increased Vaccination In 2009 H1N1 School-Located Influenza Vaccination Programs. Ambrose CS, et al. Poster Session: March 29, 2011 Time: 10 - 11 AM, 3 - 4 PM; Columbia Hall, Poster # 25171
  • The Impact of School-Located Influenza Vaccination Programs on Student Absenteeism: A Review of the US Literature. Hull, HF, et al. Poster Session: March 29, 2011 Time: 10 - 11 AM, 3 - 4 PM; Columbia Hall, Poster # 25129
  • Current Experience with School-Located Influenza Vaccination Programs in the United States:  A Review of the Medical Literature. Hull, HF, et al. Poster Session: March 29, 2011 Time: 10 - 11 AM, 3 - 4 PM; Columbia Hall, Poster # 25160

MedImmune abstracts to be presented at NIC on influenza vaccines in specific populations and/or groups include:

  • A Post-Licensure Evaluation of the Safety of Live Attenuated Influenza Vaccine in Individuals 5 to 49 Years of Age. Toback, SL, et al. Poster Session: March 29, 2011 Time: 10 - 11 AM, 3 - 4 PM; Columbia Hall, Poster # 25173
  • A Postmarketing Evaluation of the Frequency of Use and Safety of Live Attenuated Influenza Vaccine in Non-Recommended Children Less Than 60 Months of Age. Toback, SL, et al. Poster Session: March 29, 2011 Time: 10 - 11 AM, 3 - 4 PM; Columbia Hall, Poster # 25166
  • Factors Associated with Increased In-Office Influenza Vaccine Coverage and Two-Dose Compliance Among U.S. Pediatricians. Toback, SL, et al. Poster Session: March 29, 2011 Time: 10 - 11 AM, 3 - 4 PM; Columbia Hall, Poster # 25177
  • Influenza Vaccination Attitudes and Beliefs Among U.S. Working Adults Attending Employer-Based Vaccination Clinics. Toback, SL, et al. Poster Session: March 29, 2011 Time: 10 - 11 AM, 3 - 4 PM; Columbia Hall, Poster # 25163
  • Maternal Outcomes in Pregnant Women Receiving Live Attenuated Influenza Vaccine. Toback, SL, et al. Poster Session: March 29, 2011 Time: 10 - 11 AM, 3 - 4 PM; Columbia Hall, Poster # 25172
  • Real-Time Assessment of the 2010-2011 Pediatric Influenza Vaccination Season. Toback SL, et al. Poster Session: March 29, 2011 Time: 10 - 11 AM, 3 - 4 PM; Columbia Hall, Poster # 25176
  • Trends in U.S. Pediatric Influenza Vaccination from 2006 to 2010. Toback, SL, et al. Poster Session: March 29, 2011 Time: 10 - 11 AM, 3 - 4 PM; Columbia Hall, Poster # 25161
  • U.S. Pediatric Influenza Vaccination by Pediatricians and Family Physicians From 2006 to 2010. Toback, SL, et al. Poster Session: March 29, 2011 Time: 10 - 11 AM, 3 - 4 PM; Columbia Hall, Poster # 25174

Additional information about the 2011 NIC conference can be found at http://www.cdc.gov/vaccines/events/nic/default.htm.

About MedImmune

MedImmune, the global biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,500 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising drug candidates, MedImmune strives to deliver life-changing products, a rewarding career to our employees and a tireless commitment to improving patient health. For more information, visit MedImmune's website at www.medimmune.com.


'/>"/>
SOURCE MedImmune
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MedImmune In-Licenses Clinical-Stage Anti-Inflammatory Monoclonal Antibody From Amgen
2. MedImmune Announces Winners of the 5th Annual Respiratory, Inflammation and Autoimmunity Research Abstract Competition
3. MedImmune Focused on Revolutionizing Cancer Care
4. MedImmune to Present Five Abstracts on RSV at Pediatric Academic Societies Annual Meeting
5. MedImmune to Present Data on RSV and Influenza at 2009 American Academy of Pediatrics National Conference & Exhibition
6. MedImmune Funds Study to Help Gain Insights Into Full Burden of RSV Disease Among Premature Infants
7. MedImmune Presents New Data Demonstrating Increased Risk for Medically Attended RSV in Late-Preterm Infants
8. MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine
9. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
10. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
11. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , March 22, 2017 ... the growing legal cannabis industry is strongly contributing to ... provides comprehensive analysis and reporting for the cannabis industry, ... create more than a quarter million jobs for American ... $7.2 billion in 2016, and is projected to grow ...
(Date:3/22/2017)... March 22, 2017  As the world,s leading non-profit ... Society (LLS) has played a role in most therapies ... which are even helping patients with other cancers and ... significant investment in cutting-edge research – more than $1 ... grow with the record-breaking sum of $4.1 million raised ...
(Date:3/22/2017)... SANTA CLARA, Calif. , March 22, 2017 ... diagnostic cardiology  solutions segment, Frost & Sullivan recognizes ... Sullivan Company of the Year Award. GE Healthcare,s ... offer end-to-end cardiac solutions has allowed it to ... competitive cardiac monitoring products space. In addition to ...
Breaking Medicine Technology:
(Date:3/22/2017)... ... March 22, 2017 , ... HealthiPASS, Inc., announces ... creating a positive patient experience. , HealthiPASS has further enhanced its predictive ... by helping them understand their financial responsibility. “Our latest release focuses on ...
(Date:3/22/2017)... CA (PRWEB) , ... March 22, 2017 , ... Nearly ... should not undergo PSA (prostate-specific antigen) screening, the cancer screening continues to stir controversy. ... 2008 because it found that the risks outweighed the benefits. Now, news from ...
(Date:3/22/2017)... ... , ... The National Association for Business Resources (NABR) has recently ... in Wellness® companies for 2017. , American Specialty Health (ASH) was honored ... for its employees. ASH is one of only nine other San Diego companies being ...
(Date:3/22/2017)... ... March 22, 2017 , ... Winter ... reduces pigmentation to enhance surgical and nonsurgical procedures—Lytera 2.0 by SkinMedica. Lytera 2.0 ... the face, neck and décolletage in as little as 4 weeks. Skin pigmentation ...
(Date:3/20/2017)... ... ... The topic of healthcare in America has become one of the most ... is that they are still left without the health insurance coverage they need in ... that an unfortunate side-effect of this scenario is that hospital emergency rooms and urgent ...
Breaking Medicine News(10 mins):